BahVideo.com
Prof Pieter Sonneveld - Erasmus University Rotterdam, Netherlands
Prof Pieter Sonneveld - Erasmus University Rotterdam Netherlands | BahVideo.com
Watch Prof Pieter Sonneveld - Erasmus University Rotterdam,  Netherlands

Prof Pieter Sonneveld - Erasmus University Rotterdam, Netherlands

0 of 5 Stars
Prof Pieter Sonneveld speaks about a trial evaluating the efficacy of bortezomib during induction and maintenance therapy on progression-free survival in patients with multiple myeloma. A higher level of complete response was seen when bortezomib was used in place of vincristine during induction and bortezomib maintenance was better tolerated than thalidomide and achieved a superior progression free survival. Prof Sonneveld goes on to discusses the results of a large scale trial which indicate that allogeneic bone marrow transplant may not be beneficial to multiple myeloma patients and to reflect on the implications of a UK based trial which suggests that treating multiple myeloma patients with zoledronic acid can extend patient survival.
Channel: www.ecancer.tv
Video Length: 0
Date Found: February 18, 2011
Category: Science
Date Produced:
View Count: 4
Flag
Related Videos
Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität,  Giessen, Germany | BahVideo.com
www.ecancer.tv

Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität, Giessen, Germany

0 of 5 Stars
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
Chair: Prof Meletios Dimopoulos - Univeristy of Athens,  Greece; Prof Hermann Einsele - Medizinische Klinik II, Wurzburg, Germany; Prof Mario Boccadoro - University of Turin, Italy; Dr Maria-Victoria | BahVideo.com
www.ecancer.tv

Chair: Prof Meletios Dimopoulos - Univeristy of Athens, Greece; Prof Hermann Einsele - Medizinische Klinik II, Wurzburg, Germany; Prof Mario Boccadoro - University of Turin, Italy; Dr Maria-Victoria

0 of 5 Stars
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität,  Giessen, Germany | BahVideo.com
www.ecancer.tv

Prof Mathias Rummel - Klinikum der Justus-Liebig-Universität, Giessen, Germany

0 of 5 Stars
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
Prof Antonio Palumbo - Molinette Hospital,  Turin, Italy and Prof Vincent Rajkumar - Mayo Clinic, Arizona, USA | BahVideo.com
www.ecancer.tv

Prof Antonio Palumbo - Molinette Hospital, Turin, Italy and Prof Vincent Rajkumar - Mayo Clinic, Arizona, USA

0 of 5 Stars
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
Prof Anton Hagenbeek - Academic Medical Center,  Amsterdam, Netherlands | BahVideo.com
www.ecancer.tv

Prof Anton Hagenbeek - Academic Medical Center, Amsterdam, Netherlands

0 of 5 Stars
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
: advertisement :
Featured
Content
Featuring websites that enhance the internet user’s experience.

Like
Like